ACR/ARHP 2013

Once Daily Pregabalin CR Improves Therapeutic Response in Patients with Fibromyalgia

By October 30, 2013

Once daily controlled-release pregabalin significantly improved time to loss of therapeutic response vs. placebo in patients with fibromyalgia, a study presented at the 2013 ACR/ARHP Annual Meeting concluded.

Lipid Changes, Infection Risk Similar for Tofacitinib-Treated Diabetic, Nondiabetic Patients with RA

By October 30, 2013

Patients with rheumatoid arthritis and diabetes mellitus had no increase in mean fasting blood glucose levels after 3 months of treatment with tofacitinib, a novel oral Janus kinase inhibitor, according to a pooled analysis of five phase 3 trials reported at the 2013 ACR/ARHP Annual Meeting.

Interphalangeal Intra-articular Injections Reduce Pain, Swelling in Hand Osteoarthritis

By October 30, 2013

Lidocaine and triamcinolone hexacetonide injected intra-articularly in interphalangeal joints reduced swelling and pain during movement in the hands of patients with osteoarthritis, results of a randomized, double-blind trial presented at the 2013 ACR/ARHP Annual Meeting concluded.

Low-Dose Diclofenac Submicron Particle Caps Well-Tolerated in OA

By October 30, 2013

At the 2013 ACR/ARHP Annual Meeting, study researchers presented that the investigational, lower-dose diclofenac submicron particle capsules were generally well-tolerated in patients with osteoarthritis.

Tanezumab Improves Pain, Physical Function in Patients with Knee or Hip Osteoarthritis

By October 30, 2013

Patients with hip or knee osteoarthritis who received subcutaneous tanezumab reported improvements in pain and physical function at all doses studied, results presented at the 2013 ACR/ARHP Annual Meeting have shown.

Intra-Articular More Efficacious Than Oral Therapy for Knee Osteoarthritis Pain

By October 30, 2013

Regarding knee osteoarthritis pain, intra-articular (IA) treatments were more efficacious than oral treatments possibly because of the integrated IA placebo effect, reported study authors at the 2013 ACR/ARHP Annual Meeting.

CZP + MTX Demonstrate Favorable Long-Term Efficacy in Active RA

By October 30, 2013

At the 2013 ACR/ARHP Annual Meeting, study authors presented that patients with active rheumatoid arthritis (RA) despite methotrexate (MTX), certolizumab pegol (CZP) + MTX maintained reduction in signs and symptoms through 5 years.

Adalimumab May Increase HbA1c Levels in Patients with RA without Diabetes

By October 30, 2013

Do tumor necrosis factor inhibitors (TNFi) improve HbA1c in patients with rheumatoid arthritis? The answer depends on the agent and on whether patients have diabetes mellitus, according to a study presented at the 2013 ACR/ARHP Annual Meeting.

Strontium Ranelate Significantly Reduces Radiological Progression in Knee Osteoarthritis

By October 30, 2013

Using a new definition of radiological progression, patients with osteoarthritis of the knee treated with strontium ranelate had a significant reduction in such progression, "suggesting a long-term beneficial effect on knee osteoarthritis-related surgery," according to a study presented at the 2013 ACR/ARHP Annual Meeting.

Epratuzumab Sustains Long-Term Efficacy in Moderate-to-Severe Lupus

By October 29, 2013

At the 2013 ACR/ARHP Annual Meeting, study investigators presented that epratuzumab was associated with sustained improvements in disease activity in patients with moderate-to-severe systemic lupus erythematosus (SLE).

BREVACTA: SC Tocilizumab + DMARD Show Lasting Efficacy Up to Week 48

By October 29, 2013

At the 2013 ACR/ARHP Annual Meeting, study authors presented data on subcutaneous tocilizumab that demonstrated long-term efficacy, including sustained ACR response rate and reduced joint damage progression over 48 weeks.

High Retention, Improvements in RA With Golimumab + Methotrexate

By October 29, 2013

A high retention rate and improvements in signs/symptoms of rheumatoid arthritis (RA) and in physical function were maintained long-term with golimumab + methotrexate therapy, investigators presented at the 2013 ACR/ARHP Annual Meeting.

Fostamatinib Improves ACR20 Response Rate in RA Patients

By October 29, 2013

Both fostamatinib regimens in the Oskira-1 Study achieved statistical improvements in ACR 20 response rate vs. placebo in patients treated with methotrexate, reported study investigators at the 2013 ACR/ARHP Annual Meeting.

Pregnant Women with RA Have Similar Incidence of Influenza-Like Illness to Those without Autoimmune Disease

By October 29, 2013

Pregnant women with rheumatoid arthritis (RA) who received an influenza vaccination had a similar incidence of influenza-like illness compared with women without autoimmune disease, a study presented at the 2013 ACR/ARHP Annual Meeting has found.

Canakinumab Prefilled Syringe Provides Greater Pain Relief than Triamcinolone Acetonide in Acute Gouty Arthritis

By October 29, 2013

Patients with acute gouty arthritis who received canakinumab administered via a prefilled syringe experienced significantly greater pain relief and reduced risk of new attacks compared with triamcinolone acetonide, a study reported at the 2013 ACR/ARHP Annual Meeting.

Several Factors Significantly Increase Mortality with Glucocorticosteroid Use for RA

By October 29, 2013

Exposure to glucocorticosteroids was associated with a significant increase in mortality, a finding that has "important implications for health care providers and people with arthritis," results of a population-based cohort study reported at the 2013 ACR/ARHP Annual Meeting.

Denosumab Increases Bone Mineral Density, Suppresses RA Progression

By October 29, 2013

Significant increases in bone mineral density (BMD) were observed after 12 months of treatment with denosumab vs. placebo in patients with rheumatoid arthritis (RA) regardless of glucocorticoid use, according to a study presented at the 2013 ACR/ARHP Annual Meeting.

Low-Dose Naltrexone Decreases Anxiety, Pain, in Patients with Fibromyalgia

By October 29, 2013

Low-dose naltrexone may be an effective, highly tolerable, and inexpensive treatment for patients with fibromyalgia, according to results of a prospective, open-label study presented at the 2013 ACR/ARHP Annual Meeting.

Total Corticosteroid Dose Reduced With Concomitant Belimumab in SLE

By October 29, 2013

A significantly smaller increase in total corticosteroid dose was seen in the belimumab treatment arms than standard therapy alone for patients with systemic lupus erythematosus (SLE), reported study investigators at the 2013 ACR/ARHP Annual Meeting.

Patients with SLE and Arterial Thrombosis May Benefit from Treatment with Aspirin

By October 29, 2013

Aspirin is a viable option in patients with systemic lupus erythematosus (SLE) at risk for—or who have had—arterial thrombosis, a study presented at the 2013 ACR/ARHP Annual Meeting concluded.

Tofacitinib, A Viable Option for Moderate-to-Severe Rheumatoid Arthritis

By October 29, 2013

Tofacitinib may be a viable option for patients with moderate-to-severe rheumatoid arthritis, according to a systematic review and meta-analysis reported at the 2013 ACR/ARHP Annual Meeting.

Colchicine Use Among Patients with Gout Significantly Reduces Incidence of MI

By October 29, 2013

Patients with gout who actively took colchicine had a significantly reduced incidence of myocardial infarction (MI) vs. never users, results of an interim analysis presented at the 2013 ACR/ARHP Annual Meeting has found.

Ixekizumab Meets or Exceeds Clinical Improvements in Patients With RA Over 64 Weeks

By October 28, 2013

Ixekizumab is well-tolerated and maintains or exceeds clinical improvements in patients with rheumatoid arthritis over 64 weeks, according to study results presented at the 2013 ACR/ARHP Annual Meeting.

No Impact of Maternal Certolizumab Pegol Exposure on Pregnancy Outcomes

By October 28, 2013

Updated analysis of pregnancy outcomes after exposure to certolizumab pegol supports previous reports suggesting no obvious or apparent impact of maternal exposure, according to data presented at the 2013 ACR/ARHP Annual Meeting.

Certolizumab Pegol Effective in Psoriatic Arthritis, Including Those with Prior TNFi Exposure

By October 28, 2013

Patients with psoriatic arthritis both with and without previous exposure to tumor necrosis factor inhibitor (TNFi) therapy reported clinical efficacy to Week 48 with certolizumab pegol, as presented at the 2013 ACR/ARHP Annual Meeting.

Brodalumab Significantly Improves Joint Pain, Physical Functioning in Psoriatic Arthritis

By October 28, 2013

Patients with psoriatic arthritis experienced significant improvement in joint pain and physical functioning when treated with brodalumab (AMG 827), a study presented at the 2013 ACR/ARHP Annual Meeting has found.

In Psoriatic Arthritis, Long-Term anti-TNF Therapy Has Deleterious Effect on Lipid Profile

By October 28, 2013

A prospective study to evaluate the long-term effect of anti-tumor necrosis factor (TNF) therapy on lipid profile in patients with psoriatic arthritis has identified a specific deleterious pattern, investigators reported at the 2013 ACR/ARHP Annual Meeting.

Sarilumab Significantly Increases Cholesterol vs. Placebo in Patients with RA

By October 28, 2013

Sarilumab 150mg and 200mg administered every other week significantly raised levels of total cholesterol and low-density lipoprotein cholesterol in patients with rheumatoid arthritis, a study reported at the 2013 ACR/ARHP Annual Meeting.

Repeat Rituximab Courses Sustain Clinical Efficacy in Patients with RA

By October 28, 2013

A sustained improvement of clinical response was seen after each retreatment course with rituximab in patients with rheumatoid arthritis (RA), with respect to Treat to Target principles and EULAR/ACR recommendations, as presented at the 2013 ACR/ARHP Annual Meeting.

Severe Vit D Deficiency Linked to RA Presence in Early Inflammatory Arthritis

By October 28, 2013

Vitamin D deficiency contributed to the presence of rheumatoid arthritis (RA) in patients with early inflammatory arthritis (EIA), according to clinical data presented at the 2013 ACR/ARHP Annual Meeting.